Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 9:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Peripheral Arterial Occlusive Disease
Interventions: PAD endovascular treatments; Other
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 1,204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 52
States / cities: Gilbert, Arizona • Glendale, Arizona • Phoenix, Arizona + 47 more

Conditions: Degenerative Osteoarthritis
Interventions: TG-C, Placebo Control; Biological
Lead sponsor: Kolon TissueGene, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 44
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more

Conditions: Idiopathic Parkinson's Disease
Interventions: PF-06669571, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 45 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: New Haven, Connecticut • Hallandale, Florida • Hollywood, Florida + 4 more

Conditions: Hematologic Malignancies, Acute Myeloid Leukemia, Lymphoid Leukemia, Chronic Myeloid Leukemia, Hodgkin's Disease, Non-Hodgkin's Lymphoma, Myelodysplastic Syndromes
Interventions: StemEx®; Drug
Lead sponsor: Gamida Cell -Teva Joint Venture Ltd.; Other
Eligibility: 12 Years to 55 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 16
States / cities: Los Angeles, California • Orange, California • Aurora, Colorado + 10 more

Conditions: Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Interventions: OPC-108459, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 9
States / cities: Washington D.C., District of Columbia • Hollywood, Florida • Jacksonville, Florida + 6 more

Conditions: ALK-positive Non-small Cell Lung Cancer
Interventions: Ceritinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 7
States / cities: Los Angeles, California • Stanford, California • South Bend, Indiana + 4 more

Conditions: Solid Tumors (Phase 1), RAS Mutation
Interventions: AN9025 oral capsule; Drug
Lead sponsor: Adlai Nortye Biopharma Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Orlando, Florida • Tampa, Florida • Houston, Texas

Conditions: Spinal Muscular Atrophy
Interventions: Nusinersen; Drug
Lead sponsor: Biogen; Industry
Eligibility: 2 Years to 15 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 4
States / cities: Boston, Massachusetts • New York, New York • Dallas, Texas + 1 more

Conditions: Ulcerative Colitis
Interventions: SAR442970, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 21
States / cities: Fairhope, Alabama • Escondido, California • Lancaster, California + 17 more

Conditions: Lumbar Radiculopathy, Lesion of Sciatic Nerve, Left Lower Limb, Lesion of Sciatic Nerve, Right Lower Limb, Lumbar Spinal Stenosis, Lumbar Spondylosis, Lumbago With Sciatica, Left Side, Lumbago With Sciatica, Right Side
Interventions: Osteopathic Manipulative Treatment (OMT); Procedure
Lead sponsor: Rowan University; Other
Eligibility: 18 Years to 84 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: East Lansing, Michigan • Stratford, New Jersey • Voorhees Township, New Jersey

Conditions: Chronic Plaque Psoriasis
Interventions: AIN457, Placebo; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 5
States / cities: Santa Monica, California • Louisville, Kentucky • High Point, North Carolina + 2 more

Conditions: GNE Myopathy
Interventions: ManNAc, Placebo; Drug · Other
Lead sponsor: Leadiant Biosciences, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 10
States / cities: Los Angeles, California • Iowa City, Iowa • Kansas City, Kansas + 7 more

Conditions: Hemorrhage, Surgical, Tonsillar Bleeding
Interventions: Tranexamic Acid Injectable Product, Normal Saline; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 2 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Davis, California • Providence, Rhode Island • San Antonio, Texas

Conditions: Lymphoma, Non-Hodgkin
Interventions: CC-99282, Rituximab, Obinutuzumab, Tafasitamab, Valemetostat; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 8
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Tampa, Florida + 5 more

Conditions: Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Src kinase inhibitor KX2-391, immunoenzyme technique, pharmacological study; Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Depth of Focus
Interventions: No intervention; Other
Lead sponsor: Johnson & Johnson Surgical Vision, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Bakersfield, California • Sioux City, Iowa • Brecksville, Ohio + 1 more

Conditions: Foot Ulcer, Diabetic
Interventions: PriMatrix Moist Wound Therapy, Standard of Care Moist Wound Therapy; Device · Other
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 15
States / cities: Los Angeles, California • Miami, Florida • Tampa, Florida + 11 more

Conditions: Multiple Myeloma
Interventions: LBH589, Lenalidomide; Drug · Combination Product
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 3
States / cities: San Francisco, California • Atlanta, Georgia • New York, New York

Conditions: Spinal Muscular Atrophy, Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type 3
Interventions: Observational study to examine safety, tolerability, and effectiveness of SPINRAZA® prescribed as part of standard of care, One time survey; Drug · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 10
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Baltimore, Maryland + 7 more

Conditions: Rhinitis, Allergic, Perennial, House Dust Mite Allergy
Interventions: 300 IR, Placebo; Biological
Lead sponsor: Stallergenes Greer; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 1,607 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Multiple Myeloma
Interventions: BL-8040 1.25 mg/kg + G-CSF, Placebo +G-CSF; Drug
Lead sponsor: BioLineRx, Ltd.; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 10
States / cities: Los Angeles, California • Gainesville, Florida • Miami, Florida + 7 more

Conditions: Central Nervous System (CNS) Lesions, Brain Metastases, Brain Neoplasms, Brain Neoplasms, Benign, Brain Tumor, Primary, Brain Tumor, Recurrent, Brain Tumors, Brain Cancer, Brain Tumor, Brain Neoplasm, Primary, Multiple Sclerosis, Multiple Sclerosis Brain Lesion, Neurofibroma, Acoustic Neuroma, CNS Tumor, CNS Lesion, CNS Metastases, CNS Cancer, CNS Lymphoma, Von Hippel Lindau, Meningioma, Glioma, Schwannomas, Neuroinflammation, Neoplasia
Interventions: RVP-001; Drug
Lead sponsor: Reveal Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 5
States / cities: New Haven, Connecticut • Boston, Massachusetts • Columbia, Missouri + 1 more

Conditions: Alzheimer's Disease
Interventions: AZD0530 100mg daily, AZD0530 125mg daily, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 55 Years to 85 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 21
States / cities: Phoenix, Arizona • Sun City, Arizona • Los Angeles, California + 17 more

Conditions: Subacromial Pain Syndrome
Interventions: dry needling, spinal manipulation, mobilization, exercise, modalities; Other
Lead sponsor: Alabama Physical Therapy & Acupuncture; Other
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Cockeysville, Maryland

Search by objective public record fields.

Observational Study to Evaluate PAD Treatment Clinical and Economic Outcomes

A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee

PF-06669571 In Subjects With Idiopathic Parkinson's Disease

Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges

Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy

A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis

Cost Effectiveness of OMT for Chronic Low Back Pain

Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis

Multi-Center Study of ManNAc for GNE Myopathy

TEAPOT Study Multisite

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment

Prospective, Multi-center, Non-interventional, Open Label, Randomized (Depth of Focus Testing Sequences), Clinical Study

Health Economic Assessment of Lower Extremity Diabetic (HEALED) Ulcers With PriMatrix

Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.

Spinraza in Adult Spinal Muscular Atrophy

Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR

A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease

Dry Needling and Manipulation vs. Mobilization, Exercise and Interferential Electrotherapy for Shoulder Impingement (Subacromial Pain Syndrome)